About Repros
Company Overview
Board of Directors and Management
Pipeline
Proellex
®
Anemia Associated with Uterine Fibroids
Uterine Fibroids
Endometriosis
Publications
Androxal
®
Male Fertility Maintenance/Improvement
Metabolic Syndrome
Publications
Clinical Trials
Proellex® Uterine Fibroids (ZP-005)
Proellex® Endometriosis (ZPE-201)
Proellex® Uterine Fibroids (ZPU-202)
Proellex® Uterine Fibroids - Anemia (ZPU-301)
Proellex® Uterine Fibroids (ZPU-303)
Proellex® Uterine Fibroids (ZPU-305)
Androxal® Secondary Hypogonadism (ZA-201)
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Major Holders
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
July 1, 2009
Repros Therapeutics Inc. Provides Update for Proellex® Clinical Program
June 5, 2009
Repros Therapeutics Inc. Establishes Scientific Advisory Board
May 11, 2009
Repros Therapeutics Inc. Reports First Quarter 2009 Financial Results and Provides Clinical Program Update
April 17, 2009
Repros Therapeutics Inc. Board Nominates Dr. Stephen Howell to Its Board of Directors
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
